Category: Health and wellness

Surge in demand for natural ingredients, initiatives for manufacturing spirulina by governments, and R&D activities of spirulina as commercial products have fueled the growth of the global spirulina market

Rise in demand for natural ingredients, promotion of the production of spirulina by government, and R&D activities for creating spirulina as commercial products have fueled the growth of the global spirulina market. On the other hand, impact on spirulina production due to climate change has hindered the growth to some extent. Nevertheless, untapped markets in the developing countries and development in cultivation technology have created multiple opportunities in the segment.

Request Sample Report at: https://www.alliedmarketresearch.com/request-sample/4222 

The arthrospira platensis segment to rule with its lion”s share throughout the forecast period

Based on type, the arthrospira platensis segment held the highest share in 2018, contributing to nearly three-fifths of the total market. Surge in healthcare awareness and incorporation of spirulina in diets as super food globally have worked as the driving factors. Arthrospira maxima, on the other hand, is projected to grow at the highest CAGR of 10.8% during the forecast period, 2019–2026.

The powder segment to remain dominant till 2026

Based on drug formulation, the powder segment accounted for more than half of the total market share in 2018 and is anticipated to maintain its top status during the estimate period. Factors such as launch of new varieties of natural food colors produced from spirulina, natural health benefits of spirulina superfood, and various government initiatives pertaining to the production of spirulina have driven the growth.

For Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/4222 

North America to rule the roost

Based on region, North America contributed to 32.3% of the total market in 2018 and is expected to dominate during the study period. Rise in the demand for naturally derived food coloring agents in the region has spurred the growth. Simultaneously, Asia-Pacific is expected to register the highest CAGR of 11.4% throughout the forecast period.

Leading Market Players

The key market players analyzed in the report include DIC Corporation, Chr. Hansen Holding A/S, Prolgae, Cyanotech Corporation, Sensient Technologies Corporation, Parry Neutraceuticals, DDW Inc., Algatec Dongtai City Spirulina Bio-engineering Co., Ltd., Algenol Biofuels Inc., and Naturex S.A. They have adopted number of strategies such as teamwork, partnerships, mergers & acquisitions, developments, joint ventures, and others to come out with flying colors.

Access KNOWLEDGE TREE (Premium on-demand, subscription-based pricing model) at: https://www.alliedmarketresearch.com/knowledgetree

Knowledge tree is a cloud-based intelligence platform that offers more than 2,000 selective, off-the-shelf reports on niche markets to enable our clients gain deep insights on the latest trends, dynamic technologies, and emerging application areas.

Similar Reports:

Drug-Device Combination Products Market – Global Opportunity Analysis and Industry Forecast, 2017-2025

Drugs for Schistosomiasis Market – Global Opportunity Analysis and Industry Forecast, 2017-2025

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of ‘Market Research Reports’ and ‘Business Intelligence Solutions.’ AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact:
David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com

Logo: https://mma.prnewswire.com/media/636519/Allied_Market_Research_Logo.jpg  

 

PORTLAND, Oregon, May 8, 2019 /PRNewswire/ — Allied Market Research published a report, titled, ‘Spirulina Market by Type (Arthrospira Platensis and Arthrospira Maxima), Application (Nutraceuticals, Cosmetics, Food & Beverages, Animal Feed, and Others), and Drug Formulation (Powder, Tablet & Capsule, Liquid, and Granule & Gelling Agent): Global Opportunity Analysis and Industry Forecast, 2019–2026.’ The report presents an in-depth analysis of the drivers, restraints, and opportunities influencing the industry. Also, it outlines current technology trends, top pocket investments, competitive landscape, and market size & share of various segments. According to the report, the global spirulina market garnered $346 million in 2018 and is anticipated to hit $779 million by 2026, growing at a CAGR of 10.6% during the forecast period, 2019–2026.

Read Full Article

In terms of region, North America is expected to hold its dominance in the global cancer biomarkers market. Increasing number of cancer cases across the region is expected to boost the market in this region. Simultaneously, Asia Pacific is also register a splendid growth in the global cancer biomarkers market during the forecast period. There are several types of cancer such as breast cancer, lung cancer, blood cancer, prostate cancer, melanoma, ovarian cancer, colorectal cancer, stomach cancer, and liver cancer. However, lung cancer is expected to register a higher growth in the global cancer biomarkers market during the forecast period.

Get PDF Brochure for Research Insights at https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=479

Research and Development to Encourage Cancer Biomarkers Market

Cancer seems to be prevailing like a wildfire across the globe. Due to increasing prevalence of cancer, it rises the need for research and development in the cancer biomarkers sector. After lung cancer, the second most common cancer is breast cancer. Cancer biomarkers have relatively less as compared to conventional line of treatment. This promotes the global cancer biomarkers market to expand during the forecast period.  Using cancer biomarkers in the drug discovery and drug development sector is projected to boost the global cancer biomarkers market to grow substantially. Alternatively, cancer biomarkers are being used in studying genomics to provide personalized treatments than symptomatic treatments. Moreover, increasing consumption of smoking tobacco and cigarettes increases the threat of cancer such as mouth cancer. This further nudges the global cancer biomarkers to broaden during the forecast period.

Request a Sample of Report at https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=479

High Investment in Healthcare Sector Elevates Growth

Healthcare organizations and governments are investing in cancer biomarkers to provide early intervention and treatment of cancer. The objective of high investments in cancer biomarkers market is to provide support to patients and their families who go through physical and emotional trauma. Several healthcare providers and national healthcare departments are relentlessly focusing on technological advancement in cancer biomarkers. Thus, the global cancer biomarkers is expected to grow at a steady rate during the forecast period.

Request For Discount On This Report – https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=479

Additionally, rising geriatric community and availability of disposable income at consumers end stimulates the global cancer biomarker market to augment.

Cancer treatment is quite high and with the emergence of cancer biomarkers makes it highly expensive, thereby restricting the growth of the global cancer biomarkers market. However, avenues that cancer biomarkers open up in cancer diagnosis and treatment are supposed to drive the global cancer biomarkers to scale up in upcoming years.

Request For Custom Research – https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=479

The global cancer biomarkers market is highly competitive and fragmented, says Transparency Market Research as per a recently published research report. The key players in the market are majorly focusing on technological advancements. They are also entering into mergers and acquisitions to expand their presence in the global market and win over the competitive nature of the global cancer biomarkers market. Some of the key player operating in the global cancer biomarkers are Abott Laboratories, Agilent Technologies, Thermo Fisher Scientific Inc., Novartis AG, and F. Hoffman-La Roche Ltd. 

Browse Press Release – https://www.transparencymarketresearch.com/pressrelease/cancer-biomarkers-market.htm

The above review is based on a TMR report, titled, ‘Cancer Biomarkers Market (Test Type – PSA Tests, CTC Tests, AFP Tests, CA Tests, HER2 Tests, BRCA Tests, ALK Tests, CEA Tests, EGFR Mutation Tests, and KRAS Mutation Tests; Disease Indication – Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma, Blood Cancer, Prostate Cancer, Ovarian Cancer, Stomach Cancer, and Liver Cancer) – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 – 2025′

Popular Research Reports by TMR:

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company”s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR”s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

TMR”s data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.

Contact
Mr. Rohit Bhisey
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY – 12207
United States
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website
: http://www.transparencymarketresearch.com
Research Blog
: http://www.europlat.org/

LOGO: https://mma.prnewswire.com/media/664869/Transparency_Market_Research_Logo.jpg

ALBANY, New York, May 8, 2019 /PRNewswire/ — Rising number of various types of cancer is supposed to boost growth in the global cancer biomarkers market. The global cancer biomarkers market is projected to grow at a CAGR of 11.8% during the forecast period 2017 to 2025. The cancer biomarkers market registered revenue of US$10.25 bn in 2016 and it is anticipated to go up to revenue worth US$27.63 bn by the end of forecast period.

Read Full Article

BURLINGTON, Massachusetts, May 1, 2019 /PRNewswire/ — Dimensional Insight®, the maker of Diver Platform™, a data management and analytics solution, today announced the results of a survey it conducted with HIMSS Analytics of 110 senior healthcare leaders. The survey found that while most healthcare organizations say they are using analytics in clinical areas, purely clinical projects are not a top area of focus for many organizations. For example, only 1 in 5 healthcare organizations is currently using analytics for population health.

Survey results show that:

  • 90% of respondents report using analytics in clinical areas.
  • Only 28.4% of respondents are using analytics for effectiveness of care projects, 21.6% are using for population health, and 10.8% are using for chronic care management.
  • Among healthcare organizations that have not yet deployed analytics but plan to do so, only 31.8% say population health will be a top focus area. 59.1% say effectiveness of care will be a top focus area.

Furthermore, the survey indicated that clinicians (physicians and nurses) are the least empowered within organizations to drive decisions through the use of analytics.

  • On a scale of 1 to 7 (1=extremely low, 7=extremely high), the average score of stakeholders to drive decisions through analytics was a 5.17.
  • On that scale, healthcare leaders rated clinical staff a 4.39 (15.1% lower than the average).

‘Clinicians will effectively use data for decision-making when it is integrated into their workflows, but that is seldom the case at this point,’ says George Dealy, vice president of healthcare solutions at Dimensional Insight. ‘The projects that healthcare organizations can more easily wrap their arms around are those that might use clinical data – such as for readmissions improvement – but are focused on improving processes that have financial implications as opposed to directly improving patient care.’

To learn more, download the full survey results at: https://www.dimins.com/white-papers/himss-clinical-analytics/.

About Dimensional Insight

Dimensional Insight® is a leading provider of analytics and data management solutions, offering a complete portfolio of capabilities ranging from data integration and modeling to sophisticated reporting, analytics, and dashboards. The company is a six-time Best in KLAS winner in healthcare business intelligence and analytics, most recently ranking #1 in 2019. Founded in 1989, Dimensional Insight has thousands of customer organizations worldwide.

Survey reveals clinicians are less empowered than executives to make data-driven decisions through analytics

Read Full Article

Don”t miss out on business opportunities in Vitamin D Therapy Market

The major factors driving the growth of this market include the growing awareness about vitamin D deficiency among consumers and the presence of a large target patient population worldwide. 

The oral route of administration dominated the vitamin D therapy market in 2018

By route of administration, the vitamin D therapy market is segmented into oral and parenteral routes of administration. In 2018, the oral route accounted for the largest share of the market. The large share of this segment can be attributed to the ease of administration, better pharmacokinetic and pharmacodynamic activity, its economy (as compared to parenteral and topical routes), and higher preference for the oral route.

Browse in-depth TOC on ‘Vitamin D Therapy Market

77 – Tables

29 – Figures  

114 – Pages  

Get 10% Free Customization on this Report: 

https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=32540026

Osteoporosis held the largest share of the applications market in 2018

Based on applications, the vitamin D therapy market is segmented into osteoporosis, rickets, skin diseases, muscle weakness, autoimmune disorders, and other applications. In 2018, the osteoporosis segment accounted for the largest share of the vitamin D therapy market. The large share of this segment can be attributed to the increasing incidence of falls and fractures in senior adults due to the elevated level of parathyroid hormones and the poor absorption of calcium from their diets.

The Asia Pacific commanded the largest share of the vitamin D therapy market in 2018

The Asia Pacific dominated the vitamin D therapy market. The large share of this regional segment can be attributed to the increasing awareness about vitamin D deficiency, supportive government policies and programs for the implementation of vitamin D deficiency treatment plans in the region, heavy air pollution, sedentary lifestyles, increasing incidence of vitamin D deficiency, decreasing sun exposure, and rising malnutrition levels.

Inquiry Before Buying: 

https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=32540026

Some of the major players in this market include Abbott (US), Sanofi (France), GlaxoSmithKline plc (UK), Pfizer Inc. (US), Merck & Co., Inc. (US), Torrent Pharmaceuticals Ltd. (India), Novartis International AG (Switzerland), Alkem Laboratories (India), Sun Pharmaceutical Industries Ltd. (India), and Cadila Healthcare Ltd. (India).

Browse Adjacent Markets: Biotechnology Market Research Reports & Consulting

About MarketsandMarkets™ 

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies” revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the ‘Growth Engagement Model – GEM’. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write ‘Attack, avoid and defend’ strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets”s flagship competitive intelligence and market research platform, ‘Knowledge Store’ connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:

Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com 
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/vitamin-d-therapy-market.asp 
Visit Our Website: https://www.marketsandmarkets.com

Logo: https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg  

CHICAGO, April 29, 2019 /PRNewswire/ — According to the new market research report Vitamin D Therapy Market by Route of administration (Oral, Parenteral), Age Group (Children, Adult, Senior Adult), Purchase Pattern (OTC, Prescription), Application (Osteoporosis, Rickets, Autoimmune Disorder, Skin Diseases) – Global Forecast to 2024′, published by MarketsandMarkets™, the Vitamin D Therapy Market is expected to grow from USD 1.9 billion in 2019 to USD 3.3 billion by 2024, at a CAGR of 11.6% during the forecast period. 

Read Full Article

About COPAN Group

With a reputation for innovation, the family-owned COPAN Group is the leading manufacturer of collection and transport systems in the world. COPAN”s collaborative approach to innovation in pre-analytics has resulted in the original FLOQSwabs™, ESwab™, FecalSwab™ and UTM™, as well as Full Laboratory Automation. For more information, visit www.copangroup.com. 

 

BRESCIA, Italy, April 26, 2019 /PRNewswire/ — COPAN is the global leader in preanalytical collection and transport devices serving the microbiology and medical communities. In the lawsuit, COPAN asserts that Svenska LABFAB has committed a willful infringement of the patent covering COPAN”s core flocked swab technology, in connection with the distribution in Sweden of products manufactured by Medical Wire & Equipment Co. Ltd. and comprising flocked swabs made by Puritan. ‘The scientific community and market universally recognize COPAN”s founder, Daniele Triva, as the inventor of flocked swabs for collecting biological specimens. That invention, in 2003, revolutionized the industry,’ said Lorenzo Fumagalli, COPAN”s General Counsel. ‘Since then, COPAN has invested an enormous amount of time and resources to develop, manufacture, and patent these innovative solutions, as well as to convince an initially skeptical market to adopt them. COPAN cannot tolerate infringements of its intellectual property rights by certain manufacturers and distributors: this Swedish litigation, together with the ongoing one against Puritan in the USA, confirms COPAN”s efforts in stopping the actions of those who we believe are violating our intellectual property rights.’

Read Full Article

Download PDF Brochure:

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=175119477

Browse in-depth TOC on ‘Healthcare Adhesive Tapes Market’
93 – Tables
43 – Figures
155 – Pages

View detailed Table of Content here:

https://www.marketsandmarkets.com/Market-Reports/healthcare-adhesive-tape-market-175119477.html

Acrylic is estimated to be the largest resin segment in the healthcare adhesive tapes market during the forecast period.

The acrylic segment is expected to account for the largest market share during the forecast period because of its better adhesion properties to a variety of substrates. Acrylic adhesive tapes are designed with high or low tack and high or low peel strength. These tapes are permeable to moisture that is measured by the moisture vapor transmission rate (MVTR). Acrylic healthcare adhesive tapes release off from body or skin without leaving adhesive residue. These tapes are preferred for stick-to-skin application because of the breathable nature compared to rubber adhesive tapes.

Request Sample Pages:

https://www.marketsandmarkets.com/requestsampleNew.asp?id=175119477

Fabric to account the largest share as a backing material in the healthcare adhesive tapes market during the forecast period.

The fabric is the most popular backing material used in the manufacturing of healthcare adhesive tapes. Fabric healthcare adhesive tapes are high in demand as they have high strength, toughness, good abrasion, and heat resistance, low creep at elevated temperatures, good chemical resistance, and excellent dimensional stability. Owing to its strength, these tapes are used for securing dressings, catheters, tubing, and wound dressing and for other medical purposes.

North America to account for the largest share of the healthcare adhesive tapes market during the forecast period.

Various factors have contributed to the growth of the North American healthcare adhesive tapes market. These factors include the rising incidence of chronic wounds, increase in the number of elderly citizens, increasing patient awareness on wound care, aging population, and technological advancements in the healthcare industry. The surgical adhesive tapes application has witnessed steady growth along with an increase in orthopedic and trauma, neurosurgery, cardiovascular, and gastroenterology. The increasing number of orthopedic procedures in the US is driving the demand for bandages and healthcare adhesive tapes.

Major vendors in the Healthcare Adhesive Tapes Market include 3M (US), Cardinal Health, Inc. (US), Nitto Denko Corporation (Japan), Johnson & Johnson Services, Inc. (US), PAUL HARTMANN AG (Germany), Avery Dennison Corporation (US), NICHIBAN Co., Ltd. (Japan), Smith & Nephew (UK), Lohmann GmbH & Co.KG (Germany), Scapa Group Plc (US), Medline Industries Inc. (US), and Essity Aktiebolag (PUBL) (Sweden).

Get 10% Free Customization on this Report:

https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=175119477

Browse Adjacent Markets: Coatings Adhesives Sealants and Elastomers Market Research Reports & Consulting

Related Reports:

Medical Adhesive Tapes Market by Type (Acrylic, Silicone, Rubber), Backing Material (Paper, Fabric, Plastic), Application (Surgeries, Wound Dressings, Secure IV Lines, Splints, Ostomy Seals) – Global Forecast to 2022

Adhesive Tapes Market by Resin Type (Acrylic, rubber, silicone), Technology (Solvent, Water and Hot-Melt-Based), Substrate (PP, Paper, PVC), Application (Packaging, Healthcare, Electrical & Electronics, Automotive), and Region-Global Forecast to 2022

About MarketsandMarkets™ 

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies” revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the ‘Growth Engagement Model – GEM’. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write ‘Attack, avoid and defend’ strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets”s flagship competitive intelligence and market research platform, ‘Knowledge Store’ connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com 

Logo: https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg

CHICAGO, April 23, 2019 /PRNewswire/ — According to the new market research report Healthcare Adhesive Tapes Market by Resin (Acrylic, Rubber, Silicone), Backing Material (Paper, Fabric, Plastic), Application (Surgery, Hygiene, Wound Dressing, Secure Iv Lines, Ostomy Seal, Splint, Bandages, Diagnostic), and Region – Forecast to 2023′, published by MarketsandMarkets™, the Healthcare Adhesive Tapes Market is projected to grow from USD 27.2 billion in 2018 to USD 37.3 billion by 2023, at a CAGR of 6.51% during the forecast period. The major factor driving the healthcare adhesive tapes market includes the increase in demand for surgeries, wound dressings, hygiene, transdermal drug delivery, and many others, owing to their advantages in many medical applications. These adhesive tapes have wide acceptability due to factors such as low cost and easy availability, as compared to traditional medical procedures.

Read Full Article

This collaboration is expected to take several forms, including joint design and implementation of clinical research, working meetings at scientific conferences like the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), and IDWeek, cross-entity working groups with diverse functional group participation, clinical trial innovations, data and protocol exchanges, and, contractual, regulatory, and systems harmonization.

‘We at the ARLG have long admired the work being done by COMBACTE to increase the efficacy of antimicrobial drug development,’ said Vance Fowler, MD, an investigator at the DCRI and co-principal investigator of the ARLG. ‘Combining our efforts will allow us to maximize the work we both do to stop the advancement of antibacterial resistance.’

Both organizations have been working toward the same mission since each launched in 2013, and now, the two groups will share their work to increase synergy and avoid duplicative efforts in clinical research.

‘We have already made efforts to expand our reach across Europe, where an increasing number of people suffer from infections caused by antibiotic-resistant bacteria,’ said Marc Bonten, MD, coordinator of COMBACTE and a professor at UMC Utrecht. ‘But by collaborating and sharing our progress with the ARLG, we can make a truly global impact beyond this population — an important consideration in a globally connected era in which epidemics travel across oceans quickly.’

As part of the agreement, the ARLG will have the opportunity to lead and coordinate U.S.-based studies for all clinical research initiated by COMBACTE, while COMBACTE will have the opportunity to lead and coordinate ARLG-initiated projects in Europe.

Earlier this year the European Clinical Research Alliance on Infectious Diseases (ECRAID) was formed, merging COMBACTE”s more than 850 clinical trial sites and 650 laboratories with the network of primary care sites coordinated by The Platform for European Preparedness Against (Re-)Emerging Epidemics (PREPARE) to form a European-wide sustainable clinical research organization for infectious diseases and antimicrobial resistance. The ARLG, with established collaborations in 19 countries, will help to expand these efforts outside of Europe. The alliance will enable innovative, flexible, and adaptive collaboration between the DCRI and UMC Utrecht.

‘This is an exciting year for PREPARE to expand its work in reducing a serious public health threat,’ said Herman Goossens, MD, coordinator of PREPARE and professor at University of Antwerp and UMC Utrecht. ‘First, we joined forces with COMBACTE by forming ECRAID, and now, we welcome a partnership with the ARLG, which will help all three organizations leverage a wider set of resources and a deeper pool of expertise.’

The ARLG is supported by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, under Award Number UM1AI104681. COMBACTE-NET, COMBACTE-CARE, and COMBACTE-MAGNET receive support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115523 | 115620 | 115737 resources of which are composed of financial contribution from the European Union Seventh Framework Programme (FP7/2007-2013) and EFPIA companies in kind contribution. COMBACTE-CDI receives support from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement n° 777362 resources of which are composed of financial contribution from the European Union”s Horizon 2020 research and innovation programme, and EFPIA. PREPARE is funded by the European Union”s FP7 Programme n° 602525. ECRAID is funded by the European Union”s Horizon 2020 Programme n° 825715.

About the Antibacterial Resistance Leadership Group (ARLG)

The Antibacterial Resistance Leadership Group (ARLG) consists of more than 50 leading experts working together to combat the antibacterial resistance crisis and improve patient care. It accomplishes this goal through a scientific agenda that prioritizes areas of unmet needs, innovates clinical trial design, and informs practice-changing guidelines. Created in 2013, the ARLG receives its funding from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health. It is facilitated by the Duke Clinical Research Institute and works under the thought leadership of an executive committee and two principal investigators: Vance Fowler, MD, of Duke University, and Henry ‘Chip’ Chambers, MD, of University of California, San Francisco.

About COMBACTE

In November 2011, the European Commission, as part of its action plan to combat the increasing threat of antimicrobial resistance, called for ‘unprecedented collaborative research and development effort to bring new antibiotics to patients,’ including the launch of the sixth, the eight and the eleventh IMI Calls for Proposals in May 2012, December 2012 and December 2013 respectively, as part of the program entitled ‘New Drugs 4 Bad Bugs (ND4BB).’ Within the ND4BB program are the COMBACTE-NET, COMBACTE-MAGNET, COMBACTE-CARE, and COMBACTE-CDI consortia, which were formed in January 2013 January, March 2015, and November 2017, respectively. The COMBACTE program management office is based in the University Medical Center Utrecht, one of the largest public health institutions in the Netherlands.

Media contact

Eric Trinthamer, UMC Utrecht
Phone: +31 6 21 55 66 58
Email: h.j.e.trinthamer@umcutrecht.nl

Mark Slagle, ARLG
Phone: +1 919-668-8031
Email: mark.slagle@duke.edu

UTRECHT, Netherlands and DURHAM, N.C., April 13, 2019 /PRNewswire/ — The U.S.-based Antibacterial Resistance Leadership Group (ARLG), part of the Duke Clinical Research Institute (DCRI) and the University Medical Center (UMC) Utrecht, the managing entity of the COMBACTE (Combatting Bacterial Resistance in Europe) consortium, will work together to solidify a comprehensive global community to combat the threat of antibiotic resistance around the world.

[[[tasteofexc

Read Full Article

Rise in the adoption of companion animals and the growing prevalence of animal diseases propel the growth of the global animal vaccines market

Surge in prevalence of animal diseases, growth in ownership of companion animal, rise in demand for pet insurance, and increase in animal health expenditure drive the growth of the global animal vaccines market. However, highly competitive meat & milk prices and unfavorable impact of veterinary vaccines on animal & human health hamper market growth. Nonetheless, rapid advancement in vaccine products and increased demand for hybrid animals worldwide is set to would provide lucrative opportunities to emerging market players in the near future.

Request Sample Report at: https://www.alliedmarketresearch.com/request-sample/1988 

DNA vaccines segment to encounter the fastest growth rate through 2025

By product type, the DNA vaccines segment is projected to grow at the highest CAGR of 7.8% during the forecast period, owing to their cost-effective nature, easy development and production, negligible risk of infection, and long term persistence of immunogenicity. However, the attenuated vaccines segment is expected to continue its dominance and occupy one-third of the global market share by 2025, due to their ability to provide stronger immunity as compared to other vaccines and reducing the need for booster vaccines later on.

Cattle segment to dominate the global market in the near future

By animal type, the cattle segment is anticipated to generate more than one-third of the global revenue by 2025, on account of increased meat & milk consumption and surge in demand for dairy products. However, the companion animal segment is expected to be the fastest growing segment from 2017 to 2025, with a CAGR of 6.4%, due to an increase in their adoption rate and rise in awareness regarding the importance of vaccines for dogs and cats.

For Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/1988 

North America to contribute the largest revenue throughout the forecast period

North America occupied almost one-third of global market revenue in 2017 and is expected to continue its dominance through 2025. The region has a high adoption rate of companion animals and has witnessed a surge in meat & milk consumption. However, Asia-Pacific is projected to register the highest CAGR of 6.5% during the forecast period, due to the rise in pet ownership and increased incidence of various zoonotic diseases.

Key market players

The key players analyzed in the report include Merck & Co., Inc., Zoetis Inc., Ceva Sant Animale, Sanofi S.A., Romvac, Vaxxinova, Biovac, Merial, and Anicon Labor GmbH. They have adopted different strategies including collaborations, joint ventures, partnerships, expansions, mergers & acquisitions, and others to gain a strong position in the industry.

Access KNOWLEDGE TREE (Premium on-demand, subscription-based pricing model) at: https://www.alliedmarketresearch.com/knowledgetree

Knowledge tree is a cloud-based intelligence platform that offers more than 2,000 selective, off-the-shelf reports on niche markets to enable our clients gain deep insights on the latest trends, dynamic technologies, and emerging application areas.

Similar Reports:

Veterinary Point of Care Blood Gas Analyzers Market – Global Opportunity Analysis and Industry Forecast, 2017-2023

Animal Therapeutics and Diagnostics Market – Global Opportunity Analysis and Industry Forecast, 2014-2022

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of ‘Market Research Reports’ and ‘Business Intelligence Solutions.’ AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact:

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com

Web: https://www.alliedmarketresearch.com

Logo: https://mma.prnewswire.com/media/636519/Allied_Market_Research_Logo.jpg  

PORTLAND, Oregon, April 9, 2019 /PRNewswire/ — Allied Market Research recently published a report, titled, Animal Vaccines Market by Product Type (Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Conjugate Vaccines, Recombinant Vaccines, and DNA Vaccines) and Animal Type (Companion animals, Cattle, Fish, Pigs, Poultry, and Sheep]: Global Opportunity Analysis and Industry Forecast, 2018 – 2025′. According to the report, the global animal vaccines market generated $8.1 billion in 2017 and is expected to garner $12.8 billion by 2025, growing at a CAGR of 5.9% during the forecast period, 2018-2025.

[[[tasteofexc

Read Full Article

Among three types of tests performed in the global HIV/AIDS diagnostics market, the rapid test (POC) segment showcases maximum market share. This is because of the rising popularity of the test owing to its swift results and easy usage. Region-wise, North America is a remarkable shareholder in the global HIV/AIDS diagnostics market. This is attributed to the growing awareness regarding different diagnosis and advanced research and development facilities in the region.

Get PDF Brochure for Research Insights at https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=26582

Rising Governments” Initiatives in Reducing AIDS Boosts HIV/AIDS Diagnostics Market

Various diagnosis tests are required for detecting the existence of the HIV virus. The AIDS/HIV diagnosis can be performed by saliva test, blood test, and viral load test. The most effective and efficient test results are acquired by ELISA test and Western Bloat Method. The growth of the global HIV/AIDS diagnostics market is fueled by the rising prevalence of AIDS worldwide and several governmental initiatives to promote the awareness about HIV/AIDS.

Furthermore, the people from the region of lower literacy rate are not aware of changing lifestyle, transmission mode of blood, and safety during sex. Such factors lead to the raised number of HIV cases. Hence, governments of various countries along with NGOs are taking approach to improve HIV diagnostics and making the diagnostics procedures easily available and accessible to the general people. Such factors are also propelling expansion in the global HIV/AIDS diagnostics market.

Request a Sample of Report at https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=26582

HIV Rapid Diagnostics Test Important to Obtain Early Results

Various countries worldwide are adopting a strategic combination of HIV testing service models on the basis of the nature of context, epidemic, available resources, and cost-effectiveness. Such combination facilitates the HIV diagnosis as soon as possible for curing the disease on time. Thus, governments of several countries have launched HIV rapid diagnostics test kits for immediate return of results and initiating treatments rapidly. Such inventions are also booting the global HIV/AIDS diagnostics market.

Request For Discount On This Report – https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=26582

Transparency Market Research (TMR) records that the global HIV/AIDS diagnostics market is witnessing a moderate level of competition. This is due to the active participation of a handful of uppermost players, who are competing against one another. However, the competition is mild also on account of a small number of products which were being approved for commercial use. The level of competition existing between potential players is likely to escalate as they are adopting various competitive pricing strategies.

Another influencing factor behind keeping the competition moderate includes high entry barriers to new aspiring players. This is because of the intense research required for developing diagnostic kits, which could be quite hectic for beginners. Moreover, until now, most of the products launched in the U.S were only used for research purposes. The dominant players in the HIV/AIDS diagnostics market are acquiring several key tactics to stay abreast with the latest trends in the market for successfully carrying out their research.

Request For Custom Research – https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=26582

Various uppermost and startup firms in the global HIV/AIDS diagnostics market are concentrating on capacity expansion through mergers and acquisitions. They are also focusing on channelizing efforts for offering cost-effective diagnostics for HIV/AIDS. On the other hand, a few vendors in the market have made impressive strides through investing in research and development and innovation or introduction of new products. Some active companies operating in the global HIV/AIDS diagnostics market are OraSure Technologies, Dickinson and Company, Becton, F. Hoffman-La Roche Ltd., and Abbott Laboratories.

Browse Press Release – https://www.transparencymarketresearch.com/pressrelease/hiv-aids-diagnostics-market.htm

The review is based on a market research report by TMR, titled, ‘HIV/AIDS Diagnostics Market (Product – Kits and Reagents and Instruments; Test Type – Rapid Tests (POC), ELISA, and Nucleic Acid Tests; End User – Hospitals, Private Diagnostic Laboratories, and Academic and Research Institutes) – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 – 2025′.

Popular Research Reports by TMR:

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company”s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR”s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

TMR”s data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.

Contact

Mr. Rohit Bhisey
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY – 12207
United States
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com
Research Blog: https://theglobalhealthnews.com/

Logo: https://mma.prnewswire.com/media/664869/Transparency_Market_Research_Logo.jpg

ALBANY, New York, April 9, 2019 /PRNewswire/ — According to experts from TMR, the global HIV/AIDS diagnostics market was valued at US$2.606 bn in 2016. The HIV/AIDS diagnostics market to become worth US$5.74 bn by 2025 end. Experts project this growth to occur at an impressive CAGR of 9.3% during the forecast period from 2016 to 2025.

[[[tasteofexc

Read Full Article

Hannah Deacon, a tireless campaigner for access to medical cannabis in the UK, led a high-profile campaign on behalf of her young son Alfie Dingley which helped change the law last year. Alfie was the first person in the UK to receive a permanent medical cannabis license, obtained by Professor Mike Barnes, ECH”s Chief Medical Officer.

Seven-year-old Alfie Dingley suffered up to 500 life-threatening seizures a month, and was admitted to hospital 48 times a year as a result of his severe epilepsy. Following successful treatment with cannabis oil, he has had only one hospital admission in a year, his seizures are controlled, and he can now live a more normal life. Although around 500,000 people in the UK have epilepsy, only one other person has been prescribed the treatment on the NHS[i].

ECH is committed to building the infrastructure that will make medical cannabis more readily acceptable and accessible, by delivering clinical education, access to consultation and treatment for people living with a range of chronic and debilitating conditions.

As ECH Patient Advocacy Specialist, Hannah will support the teams behind ECH, the network of Medical Cannabis clinics and The Academy, an online educational platform, to support the safe and effective use of medical cannabis. She will advise on the specific needs of patients who are navigating the system since the Home Office decision in November, and are still struggling to access medical cannabis. She will also help to ensure ECH”s innovation in medical cannabis treatment best reflects the needs of patients with high unmet needs, including those living with chronic pain, neurological and psychiatric conditions.

Hannah Deacon commented: ‘Families were delighted when the law changed last year, they thought their battle was over. Now they are in despair. The families I speak to every day have exhausted all their options, and are suffering terribly but they still can”t access the medical cannabis that could help them like it has helped Alfie.

I”m delighted to join ECH to continue to fight the battle to overcome barriers to medical cannabis in the UK, support better education and ensure patients right across the country get the access they need and the help they deserve.’

Stephen Murphy, ECH Group Managing Director, added: ‘The legalisation of prescription cannabis has given people with chronic illnesses hope, and it is ECH”s mission to fulfil that. We are thrilled that Hannah Deacon, who understands what it means to fight for the care her son deserves, has come onboard to share her insight and counsel on what more we can do to make sure that other patients – like Alfie – are no longer denied the treatment they need to survive.’

ABOUT ECH

ECH is at the forefront of transforming the medical cannabis industry to improve treatment options for patients with chronic and debilitating conditions. Supported by a team of world-leading medical advisors, our unrivalled group of companies take a comprehensive approach to improving access to medical cannabis for eligible patients by providing key infrastructure and educational services.

Committed to opening up the UK market to improve access to medical cannabis, ECH opened the first of a planned network of specialist medical cannabis clinics in March 2019. The Medical Cannabis Clinics are led by Clinical Director, Professor Michael Barnes, who also founded The Academy of Medical Cannabis, the only online education platform which seeks to improve responsible use of medical cannabis. Professor Barnes is the world”s foremost expert in medical cannabis whose 2016 report ”Cannabis: The Evidence for Medical Use” helped pave the way for legalisation of medical cannabis.

Our wider portfolio includes market intelligence firm Prohibition Partners, the foremost arena to share knowledge and shape the future of medical cannabis in Europe, Cannabis Europa and CBD brand group Amkeu. These holdings provide ECH with a fundamental anchor in the cannabis investment market, while helping it define this emerging industry.

[i] https://www.mirror.co.uk/news/uk-news/kids-forced-leave-uk-survive-14150885

Logo: https://mma.prnewswire.com/media/813128/ECH_Logo.jpg

 

 

LONDON, April 3, 2019 /PRNewswire/ — ECH, the group of companies behind the launch of the UK”s first medical cannabis clinic, has today reinforced its ambition to expand patient access by appointing Hannah Deacon as its Patient Advocacy Specialist.

[[[tasteofexc[[[tasteofexc

Read Full Article